Thursday, June 09, 2011
Daily Clinical Updates from the Annual Oncology Meeting in Chicago | prIME Oncology slides/interviews - Oza/Monk
Release Date June 7, 2011 | Expiration Date June 7, 2012 | |||||||
| Faculty | ||||||||
| Melanoma: Antoni Ribas, MD UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States |
Ovarian Cancer:
Amit Oza, MD
Princess Margaret Hospital
Toronto, Ontario, Canada
| Genitourinary Malignancies: Dean Bajorin, MD Memorial Sloan-Kettering Cancer Center New York, New York, United States | ||||||
| Vernon Sondak, MD H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States | Bradley Monk, MD Creighton University School of Medicine at St Joseph's Hospital and Medical Center Phoenix, Arizona, United States | |||||||
Tuesday, June 07, 2011
2011 ASCO Annual Meeting | About the Meeting | What's New in 2011 | Clinical Trials Day
Note: clicking on the link below brings up a pdf file
Clinical Trials Day
Clinical Trials Day • Monday, June 6 is Clinical Trials Day at the Annual Meeting and will feature sessions that focus on a variety of themes relevant to the progress of clinical trials. The series of events will begin on Sunday night with the session “Early-phase Cancer Clinical Trials: Are the Goals Therapeutic or Scientific?” Sessions taking place on Monday are listed below. For additional session information, see the Clinical Trials track listing.Monday, June 06, 2011
Australia: 2011 Consumers Reforming Health Conference
Welcome to the 2011 Consumers Reforming Health Conference, the inaugural international conference for community engagement in health care. The conference will run from 18th - 20th July 2011 with a public lecture on Sunday 17th of July 2011 at the Melbourne Convention and Exhibition Centre.
The Consumers Reforming Health conference is a conference developed specifically for those with interest in involving consumers in health care, policy and governance. The conference upholds the essential principle that consumer participation is fundamental for health development, clinical governance, community capacity building and health outcomes.
The program aims to demonstrate and enhance this proposition by exploring the experiences, frameworks and practical strategies of participation in a number of health sectors among a diverse range of relevant stakeholders. It intends to broker some new learnings on core principles for future change.
Join other like minded professionals and consumers for the first Consumers Reforming Health conference, Melbourne, 18-20th July 2011.
press release: NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®... -- CHICAGO, June 5, 2011 /PRNewswire/ --
Note: phase 2, single agent study, see tables 1-3 for additional information
Sunday, June 05, 2011
Primary Care Doctors and Medical Oncologists Have Different Concerns About Providing Survivorship Care | Cancer.Net ASCO/Patient Pages
"It’s important for patients to talk with both their oncologist and primary care doctor and make sure that information about their treatment and follow-up care recommendations is being shared."
NOCC Breaking News! NOCC SURVIVORS ON THE DR. OZ SHOW!
NOCC survivors did a fantastic job on The Dr. Oz Show last week! Our sincere thanks to Dr. Oz, who is an advocate of ovarian cancer awareness, and to those survivors who participated in the show. Together, we are making a difference. Together, we are breaking the silence!
If you missed the show, you can watch it by clicking on the links below.
For Part 1 of The Dr. Oz Show, please click HERE.
For Part 2 of The Dr. Oz Show, please click HERE.
For Part 3 of The Dr. Oz Show, please click HERE.
For Part 4 of The Dr. Oz Show, please click HERE
Study Finds Drug (Exemestane) Offers Option in Preventing Breast Cancer - NYTimes.com
Important Note: read the whole article for context of message
extract: Balancing Access and Evaluation in the Approval of New Cancer Drugs, June 8, 2011 — JAMA (patient safety etc)
".....Patients with cancer who lack effective treatment desperately seek novel interventions that might extend their lives. They do not have time to wait for the US Food (blogger's note - or any other nation) and Drug Administration's (FDA’s) regular approval process, which requires that sponsors demonstrate “substantial evidence of clinical benefit (or efficacy) from adequate and well-controlled investigations.”........
Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer, June 8, 2011 JAMA
Objectives To define characteristics of orphan cancer drugs and their pivotal clinical trials and to compare these with nonorphan drugs.
.......More treated patients had serious adverse events in trials of orphan drugs vs trials of nonorphan drugs (48% vs 36%; odds ratio, 1.72; 95% confidence interval, 1.02-2.92; P = .04).
Conclusion Compared with
pivotal trials used to approve nonorphan cancer drugs, pivotal trials
for recently approved orphan drugs for
cancer were more likely to be smaller and to use
nonrandomized, unblinded trial designs and surrogate end points to
assess
efficacy.
(discussion on stats) extract/s: (Avastin) Bevacizumab and Cancer Treatment-Related Mortality, June 8, 2011 — JAMA
plus Related letters Bevacizumab and Cancer Treatment-Related Mortality Cornelis J. A. Punt, Linda Mol, Miriam Koopman JAMA. 2011;305(22):2292.doi:10.1001/jama.2011.758 Extract Full Text Full Text (PDF) Bevacizumab and Cancer Treatment-Related Mortality Patricia B. Cerrito JAMA. 2011;305(22):2292.doi:10.1001/jama.2011.759 Extract Full Text Full Text (PDF) Bevacizumab and Cancer Treatment-Related Mortality—Reply Shenhong Wu, Vishal Ranpura, Sanjay Hapani JAMA. 2011;305(22):2292-2293.doi:10.1001/jama.2011.760 Extract Full Text Full Text (PDF)
free full access paper + video: Effect of Screening on Ovarian Cancer Mortality, June 8, 2011 JAMA The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
also:
JAMA Report Video This JAMA Report summarizes key findings from the article in video format and includes an interview with one of the authors.
The video script and links to the video are available at http://pubs.ama-assn.org/media/2011jer/0604.dtl#vnrscript
JAMA REPORT (VIDEO SCRIPT)
YEARLY OVARIAN CANCER SCREENING ASSOCIATED WITH NO REDUCTION IN DEATH AND INCREASED FALSE POSITIVE TESTS
MLH1/MSH2/MSH6 (Lynch Syndrome) Study Identifies Genetic Mutations Associated With Cancer Risk For Hereditary Cancer Syndrome - media
"The researchers found significant differences in estimated cumulative cancer risk between the 3 mutated genes......"
"This analysis of a nationwide series of 537 families with Lynch syndrome provides age- and gene-specific risk estimates for each tumor of the spectrum. The results should help clarify the phenotypic differences between MSH6, MLH1, or MSH2 mutation carriers and highlight the clinical significance of the risk of gynecological (and especially ovarian) cancers," the researchers conclude."
Subscribe to:
Posts
(
Atom
)
